The Week In Cannabis: FDA Approves Epidiolex, Brett Favre Joins The Industry, Stocks In Red 2020/08/07 20:30:38 Benzinga
In a week where markets were up, cannabis stocks were mostly declining. The week started off on a good note, with GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) and Greenwich Biosciences Inc. jointly announcing FDA approval for Epidiolex, an oral solution aimed to manage seizures related to tuberous sclerosis complex. The companies said the age range includes patients one year of age and older. Besides the new indication, EPIDIOLEX, which is plant-derived CBD medicine, can also help those suffering from seizures linked to Lennox-Gastaut and Dravet syndromes. Initially, the medicine is approved by the FDA for treating both syndromes in patients two years of age and older. Illinois adult-use cannabis sales remained strong in July, hitting around $61 million. That’s a monthly increase of roughly 28%. In Michigan, speculation mounted around new cannabis licenses. According to some reports, starting Nov. 1, businesses and individuals aspiring a recreational marijuana license in Michigan may no longer need to be a medical marijuana license holder.
GW Pharma shares slide 12% after company swings to loss during pandemic 2020/08/07 15:24:43 MarketWatch
Shares of GW Pharmaceuticals PLC undefined slumped 12% Friday, after the company swung to a loss in the second quarter, hurt by the effect of the coronavirus…
GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress 2020/08/06 20:00:00 GlobeNewswire
- Total revenue increased 68 percent to $121.3 million - - Epidiolex approved in the U.S. for seizures associated with TSC, launch expected this month - -…
GW Pharmaceuticals Q2 2020 Earnings Preview (NASDAQ:GWPH) 2020/08/05 17:28:38 Seeking Alpha
GW Pharmaceuticals (NASDAQ:GWPH) is scheduled to announce Q2 earnings results on Thursday, August 6th, after market close. The consensus EPS Estimate is -$
FDA Approves CBD Meds From GW Pharmaceuticals To Treat Seizures 2020/08/03 17:56:35 Benzinga
GW Pharmaceuticals plc (NASDAQ: GWPH ) and Greenwich Biosciences Inc. jointly announced FDA approval for EPIDIOLEX , an oral solution aimed to manage seizures related to tuberous sclerosis complex. The companies said the age range includes patients one year of age and older. Besides the new indication, EPIDIOLEX, which is plant-derived CBD medicine, can also help those suffering from seizures linked to Lennox-Gastaut and Dravet syndromes. Initially, the medicine is approved by the FDA for treating both syndromes in patients … Full story available on Benzinga.com
The Daily Biotech Pulse: Sanofi-GSK Land $2.1M Funding For Coronavirus Vaccine, D-Day For GW Pharma, FDA Nod For Roche 2020/07/31 07:45:00 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 30) Achieve Life Sciences Inc (NASDAQ: ACHV) Annexon Inc (NASDAQ: ANNX) (IPOed July …
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings 2020/07/26 13:54:59 Benzinga
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks. Although there were promising updates from some coronavirus vaccine makers, negative headlines plagued Novavax, Inc. (NASDAQ: NVAX ) and Moderna Inc (NASDAQ: MRNA ), sending their stocks lower by 4.7% and 23%, respectively, for the week. The week saw the listing of 4 biopharma companies on the Nasdaq, which raised a combined $772.9 million. Here are the key catalysts for the unfolding week. Conferences: Alzheimer's Association International Conference, or AAIC, to be held virtually: July 27-31 PDUFA Dates The FDA is set to rule on Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE ) NDA for UX007, its investigational drug for long-chain fatty acid oxidation disorders. (Friday) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) has a PDUFA action date, with the FDA due to announce its verdict on the company's sNDA for Epidiolex for the treatment of seizures associated with tuberous sclerosis complex.
Top Analyst Upgrades and Downgrades: Apple, AT&T, CenturyLink, Fortinet, Gap, GW Pharma, Halliburton, Marvell, Schlumberger, Wells Fargo, Western Digital and More 2020/07/15 13:11:12 24/7 Wall street
GW Pharmaceuticals stock slips after Stifel analyst backs off long-standing bullish view 2020/07/15 12:22:47 MarketWatch
Shares of GW Pharmaceuticals PLC undefined fell 0.4% in premarket trading, after Stifel Nicolaus analyst Paul Matteis downgraded the maker of the…
Cannabis Stock Gainers And Losers From July 14, 2020 2020/07/14 21:11:53 Benzinga Feeds
Gainers BIOHARVEST SCIENCES INC (OTC: CNVCF) shares closed up 29.55% at $0.10 Intec Pharma (NASDAQ: NTEC ) shares closed up 13.83% at $0.30 Bloom Energy (NYSE: BE ) shares closed up 8.18% at $13.09 High Tide (OTC: HITIF ) shares closed up 6.91% at $0.12 Cipher Pharms Inc (OTC: CPHRF ) shares closed up 6.83% at $0.96 GW Pharmaceuticals (NASDAQ: GWPH ) shares closed up 5.56% … Full story available on Benzinga.com
GW Pharmaceuticals (GWPH): Investments in manufacturing and international expansion serve as strong growth drivers 2020/05/12 19:51:46 news.alphastreet.com
GW Pharmaceuticals plc (NASDAQ: GWPH) has seen its stock gain over 17% in the past one month. The company delivered topline growth of over 200% in the first quarter of 2020 while net loss narrowed to $8 million from $50.1 million in the prior-year period. GW benefited from the control it has over its manufacture […]
GW Pharma Pops 9% After-Hours As Epidiolex Smokes Expectations 2020/05/12 05:54:33 Smarter Analyst
Cannabinoid prescription medicines stock GW Pharmaceuticals (GWPH) has reported particularly strong first quarter earnings results, with US sales of Epidiolex at $116.1M, up … The post GW Pharma Pops 9% After-Hours As Epidiolex Smokes Expectations appeared first on Smarter Analyst .
GW Pharmaceuticals sells more of CBD-derived epilepsy drug than expected, stock rises 2020/05/11 20:09:20 MarketWatch
GW Pharmaceuticals PLC undefined shares rose 2.6% in the extended session Monday after the U.K.-based company sold much more of its cannabis derived epilepsy…
GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress 2020/05/11 20:00:00 GlobeNewswire
- Total revenue of $120.6 million - - Total Epidiolex® net product sales of $116.1 million - - Conference call today at 4:30 p.m. EDT – LONDON and…
insurance market UAE, United Arab Emirates Online Insurance Market, UAE Fintech Market, Number of Insurance Lives Covered UAE, Car Dealership Sales Insurance 2020/04/29 09:09:58 Ken Research
UAE Online Insurance Industry, Motor Insurance Declining Premium UAE, Life Insurance GWP Online UAE, Individual Life GWP Online UAE, Online Brokers in UAE.